ArticleOPEN ACCESS

Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: A new rationale supporting CD44-induced AML differentiation therapy

Leukemia
DOI: 10.1038/leu.2016.221
25Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Gadhoum, S. Z., Gadhoum, N. Y., Abuelela, A. F., & Merzaban, J. S. (2016, December 1). Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: A new rationale supporting CD44-induced AML differentiation therapy. Leukemia. Nature Publishing Group. https://doi.org/10.1038/leu.2016.221

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free